Evidence map›Paper›PMID 42558941›Full record

ArticleExploration of targeted anti-tumor therapy2026

Dendritic cell-based immunotherapy modulates the systemic inflammatory profile in a 4T1 breast cancer model.

Tauana Christina Dias, Jéssica Ferreira Vieira, Katiane Tostes, Polyana Barbosa Silva, Angela Maria Moed Lopes, Gabriela Karam Rebolho, Eddie Fernando Candido Murta, Lidia Maria Rebolho Batista Arantes, Márcia Antoniazi Michelin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Exploration of targeted anti-tumor therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tauana Christina DiasOncology Research Institute (Instituto de Pesquisa em Oncologia, IPON), Federal University of the Triângulo Mineiro (Universidade Federal do Triângulo Mineiro, UFTM), Uberaba 38025-350, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0002-7293-2937
Jéssica Ferreira VieiraOncology Research Institute (Instituto de Pesquisa em Oncologia, IPON), Federal University of the Triângulo Mineiro (Universidade Federal do Triângulo Mineiro, UFTM), Uberaba 38025-350, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0003-3556-9849
Katiane TostesMolecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, São Paulo, Brazil.ORCID https://orcid.org/0000-0002-8312-9269
Polyana Barbosa SilvaOncology Research Institute (Instituto de Pesquisa em Oncologia, IPON), Federal University of the Triângulo Mineiro (Universidade Federal do Triângulo Mineiro, UFTM), Uberaba 38025-350, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0002-6691-1144
Angela Maria Moed LopesOncology Research Institute (Instituto de Pesquisa em Oncologia, IPON), Federal University of the Triângulo Mineiro (Universidade Federal do Triângulo Mineiro, UFTM), Uberaba 38025-350, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0002-8961-1777
Gabriela Karam RebolhoMolecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, São Paulo, Brazil.ORCID https://orcid.org/0000-0001-8500-1819
Eddie Fernando Candido MurtaOncology Research Institute (Instituto de Pesquisa em Oncologia, IPON), Federal University of the Triângulo Mineiro (Universidade Federal do Triângulo Mineiro, UFTM), Uberaba 38025-350, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0003-4014-1345
Lidia Maria Rebolho Batista ArantesMolecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, São Paulo, Brazil.ORCID https://orcid.org/0000-0001-8230-1218
Márcia Antoniazi MichelinOncology Research Institute (Instituto de Pesquisa em Oncologia, IPON), Federal University of the Triângulo Mineiro (Universidade Federal do Triângulo Mineiro, UFTM), Uberaba 38025-350, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0003-0842-8805

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: Breast cancer remains a major cause of cancer-related mortality in women, particularly in advanced stages where therapeutic options are limited. While immune checkpoint inhibitors (ICIs) have improved outcomes in a subset of patients, many do not respond, highlighting the need for alternative immunotherapeutic strategies. This study evaluated the effect of dendritic cell (DC)-based immunotherapy on tumor growth and on the inflammatory profile of peritoneal myeloid cells in a 4T1 murine breast cancer model. Methods: BALB/c mice bearing 4T1 breast tumors were treated with bone marrow-derived DC-based immunotherapy. Tumor volume was monitored over time, and CD14 Results: DC-based immunotherapy was associated with a non-significant trend toward reduced tumor volume and a marked suppression of key proinflammatory cytokines: IL-12 ( Conclusions: DC-based immunotherapy modulates the systemic/peritoneal inflammatory profile and attenuates tumor-promoting inflammation. This strategy may offer therapeutic benefit for patients with breast cancer who are unresponsive to conventional or ICI-based treatments and supports its further evaluation in translational studies.

Indexed as

dendritic cell, immunotherapy, breast cancer, 4T1mice, inflammation

Identifiers

PMID42558941
PMCPMC13439114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.